Amplifon stock reacts to GN Hearing weakness as analysts lift targets
Published on 08/22/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amplifon S.p.A. (ISIN IT0004056880) stock has come under pressure in recent sessions, with the share price closing at 11.68 EUR on August 20, 2026 on the Borsa Italiana, down 10.9% from the level at the start of the year according to recent sector coverage dated August 21, 2026.
The move follows softer figures from GN Hearing for the second quarter of 2026, which have weighed on sentiment across the hearing-care space, just as Amplifon reports improving revenue growth, margins and cash generation in its own first-half 2026 results.
For investors, the contrast between near-term share price weakness and strengthening operating metrics has become a central theme in the Amplifon stock story.
Share price under pressure despite recent rebound
Recent commentary on the hearing-aids sector highlights that Amplifon shares closed at 11.68 EUR on August 20, 2026, representing a decline of 10.9% versus the opening level of 2026, and signaling that the stock is still trading below its early-year range even after recent corporate milestones. This sector overview also notes a subsequent close at 11.85 EUR on August 21, 2026, which corresponded to a daily change of minus 2.99% compared with the prior session, underlining that the short-term trend remains soft despite a modest intraday rebound.
Technical analysis from an Italian market portal shows that on August 20, 2026 the stock opened the session at 12.47 EUR, close to the previous day’s low, and then weakened through the day to finish at 12.22 EUR, described as being in proximity to the session’s low, with an update timestamp of 9:51 a.m. local time. This technical comment places the stock within a short-term pattern where successive intraday lows between 12.87 EUR and 11.96 EUR have emerged, reinforcing the picture of ongoing volatility.
Market data aggregations referencing Amplifon’s international over-the-counter listing indicate a market capitalization of $3.937 billion and a price-to-earnings ratio of 21.83 as per a multi-company valuation table updated in 2025, giving a broad sense of the group’s equity valuation relative to global peers, although investors now pay more attention to the latest 2026 numbers when assessing value.
First-half 2026 results show improving growth and margins
While the share price has softened, the latest first-half 2026 figures paint a more constructive picture for Amplifon’s underlying business. A recent earnings summary reports that revenue in the first six months of 2026 rose to 1.19 billion EUR, with an EBITDA margin of 25.1% and EBITDA of 298 million EUR.
The same overview indicates that the EBITDA margin increased by 0.7 percentage point compared with the prior-year period, and EBITDA grew by 3.8%, pointing to a combination of moderate top-line expansion and efficiency gains. For the second quarter of 2026 alone, revenue is stated at 606 million EUR, up 2.2% versus the second quarter of 2025, with an organic revenue increase of 4.7% that is characterized as the strongest organic growth rate in two years.
From a cash perspective, the first half of 2026 sees the adjusted free cash flow rising to 68 million EUR, up from 40 million EUR in the first half of 2025, a difference of 28 million EUR that translates into a 70% increase year-over-year. This improvement in cash generation gives Amplifon more flexibility to invest in expansion, absorb integration costs and support shareholder returns over time.
Sector drag from GN Hearing’s Q2 2026 numbers
The pressure on Amplifon stock in August 2026 is linked in part to weaker-than-expected second-quarter results at GN Hearing, a major supplier in the hearing devices market. The sector report covering August 20, 2026 notes that GN Hearing’s revenue in the second quarter of 2026 fell to 273 million EUR, with an adjusted EBITDA margin declining to 18.1%, and an organic revenue change of minus 2% compared with plus 8% organic growth in the prior-year quarter.
These figures have been interpreted as a sign of slower momentum in parts of the hearing-aid value chain, and the negative surprise at GN Hearing is described as a catalyst for selling pressure in Amplifon shares on August 20, 2026. For investors, the contrast between GN Hearing’s contraction and Amplifon’s positive organic growth rate of 4.7% in the same quarter offers a nuanced picture: sector sentiment turned more cautious, but Amplifon’s own revenue trajectory remains upward.
In practice, this means that short-term stock moves are now driven as much by peers’ headlines as by Amplifon’s own results. The reaction to GN Hearing shows how quickly external data can overshadow individual company progress, even when the internal metrics are improving.
Analysts lift ratings and targets as GN Hearing deal reshapes outlook
A separate Italian financial news article dated August 22, 2026 examines how Amplifon’s planned collaboration and strategic move involving GN Hearing has changed analysts’ perceptions of the stock. In that piece, EBITDA synergy potential from the GN Hearing initiative is quantified at 60 million EUR to 80 million EUR by 2029, framed as an important driver for medium-term operating leverage.
The article explains that Amplifon closed the first half of 2026 with net profit of 102 million EUR, a year-over-year increase of 12%, supported by revenue growth to 1.19 billion EUR and the EBITDA margin improvement to 25.1%, reinforcing confidence in the group’s ability to convert sales into earnings. It also notes that the shares have gained roughly 10% over the last month on the Milan exchange, at one point trading above 12 EUR, and reaching 11.8 EUR on the latest referenced session, with a total equity market value of 3.2 billion EUR.
On the back of these developments, several sell-side houses have adjusted their views and target prices. One section of the same coverage outlines that rating upgrades to buy or overweight, alongside target-price revisions mostly in the mid-teens EUR range, have been issued through late July and August 2026, reflecting increased confidence that the GN Hearing collaboration and Amplifon’s organic growth can support higher earnings through 2027 and beyond.
The consensus snapshot presented there points to a mix of nine hold and eight buy recommendations, with an average target price of 13.7 EUR, indicating upside of more than 10% compared with the latest quoted level around 11.8 EUR. This target gap, combined with the stock’s discount of about 40% versus certain peers on the 2027 enterprise-value-to-EBITDA multiple, is cited as a valuation argument by more optimistic analysts.
Consensus metrics and valuation context
Additional consensus data available through a European equity platform for Amplifon shows a mean analyst stance categorized as outperform, based on contributions from 16 analysts. A snapshot linked to late August 2026 lists the last closing price at 11.85 EUR and an average target price of 13.44 EUR, implying a spread of 13.45% between the current market level and the consensus target.
This spread aligns broadly with the 13.7 EUR average target described in the Italian article, reinforcing the message that the sell-side community sees moderate upside potential from current price levels. For investors, the presence of both hold and buy ratings suggests a divided but generally constructive outlook, with upside framed more in terms of earnings delivery and synergy realization than dramatic multiple expansion.
In terms of valuation, an international comparison table that includes Amplifon’s over-the-counter symbol references a market capitalization of $3.937 billion and a price-to-earnings ratio of 21.83, highlighting that the company trades at what can be considered a quality multiple, but not an extreme premium, relative to global healthcare and consumer peers. However, the more granular EV-EBITDA analysis to 2027 in the Italian article is increasingly used as a benchmark by those focusing on cash-flow and operating leverage.
Operational momentum and free cash flow strength
Beyond headline revenue and margins, the first-half 2026 numbers underscore a key improvement in free cash flow generation. The rise in adjusted free cash flow from 40 million EUR in the first half of 2025 to 68 million EUR in the first half of 2026 represents a 70% increase, which materially strengthens Amplifon’s capacity to finance both organic expansion and integration of strategic initiatives such as the GN Hearing collaboration.
That increase is particularly notable because it comes alongside only moderate reported revenue growth of 2.2% for the second quarter, implying that management has tightened working capital, optimized capital expenditure or improved the cash conversion cycle. For equity holders, sustained double-digit growth in net profit and such a step-up in free cash flow provide a buffer against cyclical volume swings and sector noise.
At the same time, the organic revenue growth rate of 4.7% in the second quarter of 2026, labeled as the strongest in two years, suggests that Amplifon is seeing renewed demand momentum in core markets. That dynamic is important for supporting the EBITDA synergy targets of 60 million EUR to 80 million EUR by 2029, because synergies in distribution, procurement and product mix typically yield better results when overlaid onto a growing top line.
Hearing-care solutions as a core business driver
Amplifon’s business model revolves around providing hearing-care solutions through a network of specialist stores and professionals, with hearing aids as a central product category. A representative offering in many markets is modern digital hearing aids that integrate features such as directional microphones, noise reduction and wireless connectivity to smartphones, designed to improve speech understanding in daily environments.
These devices are typically fitted based on audiometric testing in Amplifon centers, where hearing-care professionals calibrate the hearing aids to the customer’s specific hearing profile. Over recent years, the company has invested in more advanced product lines and personalized service protocols, allowing for more precise fitting and follow-up, which in turn support customer satisfaction and retention.
From an investor perspective, the demand for such products is supported by structural trends such as aging populations and greater awareness of hearing health. As more people seek solutions earlier and are willing to pay for better-quality devices, Amplifon’s ability to offer a differentiated portfolio and to capture recurring service revenue becomes a key source of long-term growth.
Amplifon stock and current market levels
As of the most recent referenced session on August 21, 2026, coverage of Amplifon indicates a closing price of 11.85 EUR on the Borsa Italiana, compared with 11.68 EUR on August 20, 2026 and a decline of 10.9% from the level at the start of 2026. That pattern underscores that, even after a mild rebound, Amplifon stock is still trading below its early-year price while analysts’ average target around the mid-13 EUR range suggests upside potential contingent on delivery of the 2026 and 2027 plans.
For retail investors, the combination of short-term volatility driven by sector events, improving first-half 2026 fundamentals, and medium-term synergy ambitions tied to GN Hearing provides a layered narrative. Near term, trading decisions will likely respond to additional news from peers and any updates on integration plans; over the medium term, sustained organic growth above 4% and steady margin gains will be central to closing the gap between the current 11.85 EUR level and the 13.44 EUR to 13.7 EUR consensus targets.
Fact box
Company: Amplifon S.p.A.
ISIN: IT0004056880
Ticker: AMP
Exchange: Borsa Italiana
Price (as of August 21, 2026): 11.85 EUR
Market cap: 3.2 billion EUR (as of August 21, 2026)
Sector / Industry: Healthcare - Hearing care and medical devices
Index membership: FTSE MIB
